Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue

Journal of Medicinal Chemistry

Volumn 52, Issue 3, 2009, Pages 655-663

  Popowycz, Florence ^a   Fournet, Guy ^a   Schneider, Cédric ^a   Bettayeb, Karima ^b   Ferandin, Yoan ^b   Lamigeon, Cyrile ^c   Tirado, Oscar M ^d   Mateo Lozano, Silvia ^d   Notario, Vicente ^d   Colas, Pierre ^b,c   Bernard, Philippe ^e   Meijer, Laurent ^b   Joseph, Benoît ^a  

^a UNIVERSITÉ LYON 1   (France)

^b STATION BIOLOGIQUE   (France)

^c GEORGETOWN UNIVERSITY   (United States)

^d Aptanomics SA   (France)

^e Greenpharma SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 AMINO 2 BUTANOL) 4 (N BENZYLAMINO) 7 (1 METHYLETHYL)IMIDAZO[2,1 F] 1,2,4 TRIAZINE; 2 (1 AMINO 2 BUTANOL) 4 (N BENZYLAMINO) 8 (1 METHYLETHYL)PYRAZOLO[1,5 A] 1,3,5 TRIAZINE; CYCLIN DEPENDENT KINASE INHIBITOR; GP 0210; GP 0212; PURVALANOL A; PYRAZOLE DERIVATIVE; ROSCOVITINE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE; PURINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; EWING SARCOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR CELL; TUMOR CELL LINE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; MALE; NUDE MOUSE; SYNTHESIS;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; HUMANS; MALE; MICE; MICE, NUDE; PURINES; PYRAZOLES; TRIAZINES;

EID: 61449244746     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801340z     Document Type: Article

References (42)

1. (a) Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006, 24, 1770-1783.
2. (b) Du, J.; Widlund, H. R.; Horstmann, M. A.; Ramaswamy, S.; Ross, K.; Huber, W. E.; Nishimura, E. K.; Golub, T. R.; Fisher, D. E. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004, 6, 565-576.
3. (c) Alvi, A. J.; Austen, B.; Weston, V. J.; Fegan, C.; MacCallum, D.; Gianella-Borradori, A.; Lane, D. P.; Hubank, M.; Powell, J. E.; Wei, W.; Taylor, A. M. R.; Moss, P. A. H.; Stankovic, T. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53- dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005, 105, 4484-4491.
4. (d) Cruz, J. C.; Tsai, L. H. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol. Med. 2004,10, 452-458.
5. (e) Smith, P. D.; O'Hare, M. J.; Park, D. S. CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease. Trends Mol. Med. 2004, 10, 445-451.
6. (f) Zhang, M.; Li, J.; Chakrabarty, P.; Bu, B.; Vincent, I. Cyclin-dependent kinase inhibitors attenuate protein hyper-phos- phorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am. J. Pathol. 2004, 165, 843-853.
7. (g) Wang, J.; Liu, S.; Fu, Y.; Wang, J. H.; Lu, Y. Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat. Neurosci. 2003, 6, 1039-1047.
8. (h) Di Giovanni, S.; Movsesyan, V.; Ahmed, F.; Cernak, I.; Schinelli, S.; Stoica, B.; Faden, A. I. Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury. Proc. Natl.Acad. Sci. U.S.A. 2005, 102, 8333-8338.
9. (i) Pareek, T. K.; Keller, J.; Kesavapany, S.; Pant, H. C.; Iadarola, M. J.; Brady, R. O.; Kulkani, A. B. Cyclin-dependent kinase 5 activity regulates pain signaling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 791-796.
10. (j) Pareek, T. K.; Keller, J.; Kesavapany, S.; Agarwal, N.; Kuner, R.; Pant, H. C.; Iadarola, M. J.; Brady, R. O.; Kulkarni, A. B. Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 660-665.
11. (k) Gherardi, D.; D'Agati, V.; Chu, T.-H. T.; Barnett, A.; Gianella-Borradori, A.; Gelman, I. H.; Nelson, P. J. Reversal of collapsing glomerulopathy in mice with the cyclin- dependent kinase inhibitor CYC202. J. Am. Soc. Nephrol. 2004, 15, 1212-1222.
12. (l) Griffin, S. V.; Krofft, R. D.; Pippin, J. W.; Shankland, S. J. Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis. Kidney jnt. 2005, 67, 977-986.
13. (m) Bukanov, N. O.; Smith, L. A.; Klinger, K. W.; Ledbetter, S. R.; Ibraghimov-Beskrovnaya, O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor Roscovitine. Nature 2006, 444, 949-952.
14. (n) Price, P. M.; Yu, F.; Kaldis, P.; Aleem, E.;Nowak, G.; Safirstein, R. L.; Megyesi, J. Dependence of cisplatin- induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J. Am. Soc. Nephrol. 2006, 17, 2434-2442.
15. (o) Rossi, A. G.; Sawatzky, D. A.; Walker, A.; Ward, C.; Sheldrake, T. A.; Riley, N. A.; Caldicott, A.; Martinez-Losa, M.; Walker, T. R.; Duffin, R.; Gray, M.; Crescenzi, E.; Martin, M. C.; Brady, H. J.; Savill, J. S.; Dransfield, I.; Haslett, C. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 2006, 12, 1056-1064.
16. (p) Wei, F.-Y.; Nagashima, K.; Ohshima, T.; Saheki, Y.; Lu, Y.-F.; Matsushita, M.; Yamada, Y.; Mikoshiba, K.; Seino, Y.; Matsui, H.; Tomizawa, K. Cdk5-dependent regulation of glucose-stimulated insulin secretion. Nat. Med. 2005, 11, 1104-1108.
17. (q) Kitani, K.; Oguma, S.; Nishiki, T. I.; Ohmori, I.; Galons, H.; Matsui, H.; Meijer, L.; Tomizawa, K. A Cdk5 inhibitor enhances the induction of insulin secretion by exendin-4 both in vitro and in vivo.J. Physiol. Sci. 2007, 57, 235-239.
18. (r) Pumfery, A.; De La Fuente, C.; Berro, R.; Nekhai, S.; Kashanchi, F.; Chao, S.-H. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr. Pharm. Des. 2006, 12, 1949-1961.
19. (s) Doerig, C.; Billker, O.; Pratt, D.; Endicott, J. Protein kinases as targets for antimalarial intervention: Kinomics, structure-based design, transmission-blockade, and targeting host cell enzymes. Biochim. Biophys. Acta 2005, 1754, 132-150.
20. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 123, 417-425.
21. Sharma Sapra, P.; Sharma, R.; Tyagi, R. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr. Cancer Drug Targets 2008, 8, 53-75.
22. Malumbres, M.; Pevarello, P.; Barbacid, M.; Bischoff, J. R. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol. Sci. 2008, 29, 16-21.
23. Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 2003, 36, 417-425.
24. Meijer; L.; Bettayeb, K.; Galons, H. (R)-Roscovitine (CYC202, Seliciclib). In Inhibitors of Cyclin-Dependent Kinases as Anti-tumor Agents; Enzyme Inhibitors Series, Volume 3Smith, P. J., Yue, E. W., Eds.; CRC Press: Boca Raton, FL, 2006; Chapter 9, pp 187-226.
25. (a) Gray, N. S.; Wodicka, L.; Thunnissen, A.-M. W. H.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S.-H.; Lockhart, D. J.; Schultz, P. G. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998, 281, 533-538.
26. (b) Chang, Y.-T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6, 361-375.
27. (a) Patani, G. A.; LaVoie, E. J. Bioisosterism: a rational approach in drug design. Chem. Rev. 1996, 96, 3147-3176.
28. (b) Moreira Lima, L.; Barreiro, E. J. Bioisosterism: a useful strategy for molecular modification and drug design. Curr. Med. Chem. 2005, 12, 23-49.
29. Raboisson, P.; Schultz, D.; Muller, C.; Reimund, J.-M.; Pinna, G.; Mathieu, R.; Bernard, P.; Do, Q.-T.; DesJarlais, R. L.; Justiano, H.; Lugnier, C.; Bourguignon, J.-J. Cyclic nucleotide phosphodiesterase type 4 inhibitors: evaluation of pyrazolo[1,5-a]-1,3,5-triazine ring system as an adenine bioisostere. Eur. J. Med. Chem. 2008, 43, 816- 829.
30. 1receptor antagonists. J. Org. Chem. 2002, 67, 8063-8071.
31. Dolzhenko, A. V.; Dolzhenko, A. V.; Chui, W.-K. Pyrazolo[1,5- a][1,3,5]triazines (5-aza-9-deazapurines): synthesis and biological activity. Heterocycles 2008, 75, 1575-1622.
32. Raboisson, P.; Schultz, D.; Lugnier, C.; Bourguignon, J. J. Efficient synthesis of 8-substituted pyrazolo[1,5-a]-1,3,5-triazines by regiose- lective acylation. Tetrahedron Lett. 2002, 43, 9501-9503.
33. Popowycz, F.; Bernard, P.; Raboisson, P.; Joseph, B. Synthesis of 8-substituted pyrazolo[1,5-a]-1,3,5-triazine derivatives via palladium- catalyzed cross-coupling reactions. Synthesis 2007, 367-374.
34. Bettayeb, K.; Sallam, H.; Ferandin, Y.; Popowycz, F.; Fournet, G.; Hassan, M.; Echalier, A.; Bernard, P.; Endicott, J.; Joseph, B.; Meijer, L. N-&-N, a new class of cell death-inducing, kinase inhibitors derived from the purine roscovitine. Mol. Cancer Ther. 2008, 7, 2713-2724.
35. (a) Dudfield, P. J.; Le, V.-D.; Lindell, S. D.; Rees, C. W. Synthesis of C-ribosyl imidazo[2,1-f][1,2,4]triazines as inhibitors of adenosine and AMP deaminases. J. Chem. Soc., Perkin Trans. 1 1999, 20, 2929-2936.
36. (b) Tzeng, C. C.; Motola, N. C.; Panzica, R. P. Synthesis of certain 5,6-diamino-as-triazines: precursors for fused heterocyclic systems. J. Org. Chem. 1983, 48, 1271-1275.
37. Rasmussen, P. B.; Boewadt, S. Ketene chemistry. 2. A general procedure for the synthesis of 2-alkoxycyclopropanecarboxylic esters and acids starting from aldehydes and ketene. Synthesis 1989, 114-117.
38. (a) Paull, K. D.; Hamel, E.; Malspeis, L., Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In Cancer Chemotherapeutic Agents; Foye, W. O., Ed.; American Chemical Society: Washington, DC, 1995; Chapter 2, pp 9-45. Also available online at http://dtp.nci.nih.gov/docs/compare/ compare.html.
39. (b) Holbeck, S. L. Update on NCI in vitro drug screen utilities. Eur. J. Cancer 2004, 40, 785-793.
40. Tirado, O. M.; Mateo-Lozano, S.; Notario, V. Roscovitine is an effective inducer of apoptosis of Ewing's sarcoma family tumor cells in vitro and in vivo. Cancer Res. 2005, 65, 9320-9327.
41. Ribas, J.; Boix, J. Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs. Exp. Cell Res. 2004, 295, 9-24.
42. Developmental Therapeutics Program NCI/NIH, http://dtp.cancer. gov/. Accessed October 2007.